Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 15/20 | 0.57 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.50 |
| ▸ | PDE8B | O95263 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199449 | 0.80 | PDE8B (0.40) | TLR7TLR8PDE8BPIK3CAADORA2A | |
| SCHEMBL2199421 | 0.79 | ADORA2A (0.41) | TLR7TLR8PDE8BPIK3CAADORA2A | |
| SCHEMBL5401994 | 0.78 | TLR7 (0.44) | TLR7TLR8PI4KAPI4K2BPI4K2A | |
| SCHEMBL2200949 | 0.74 | PDE8B (0.41) | TLR7TLR8PDE8BPI4KAPI4K2B | |
| SCHEMBL2201635 | 0.72 | TLR7 (0.44) | TLR7TLR8PDE8BADORA2A | |
| SCHEMBL2197738 | 0.71 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL565852 | 0.70 | PDE8B (0.44) | TLR7TLR8PDE8B | |
| SCHEMBL25816227 | 0.70 | TLR7 (0.66) | TLR7TLR8 | |
| SCHEMBL562562 | 0.70 | TLR7 (0.47) | TLR7TLR8PDE8BADORA2A | |
| SCHEMBL2196854 | 0.70 | TLR7 (0.47) | TLR7TLR8PDE8BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269781-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | TLR7 38/4885TLR8 34/4885PDE8B 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.